Efficacy of a new combined larvicidal-adulticidal ultralow volume formulation against Aedes aegypti (Diptera: Culicidae), vector of dengue

Efficacy of a new combined larvicidal-adulticidal ultralow volume formulation against Aedes aegypti (Diptera: Culicidae), vector of dengue
复制标题

DOI:
10.1007/s00436-008-1294-8
复制
发表时间:
2009-04-01
影响因子:
2
通讯作者:
Masuh, Hector
Masuh, Hector
中科院分区:
医学3区
文献类型:
--
作者:
Lucia, Alejandro;Harburguer, Laura;Masuh, Hector

文献摘要

被引文献

相似文献

开发了一种新的超低容量制剂(ULV),其中含有氯菊酯作为杀成虫活性成分和昆虫生长调节剂(IGR)吡丙醚作为杀幼虫剂,并在米西奥内斯(阿根廷)万达的田间试验中对其效力进行了评价。在两个独立的研究区域喷洒:一个区域喷洒15%氯菊酯加3%吡丙醚的超低容量制剂,另一个区域仅喷洒15%氯菊酯。保留第三个未处理区域作为对照。在处理区和对照区放置装有成蚊的哨兵笼和装有埃及伊蚊幼虫III/IV的罐子。使用20 L水容器测试制剂的残留活性。氯菊酯15% +吡丙醚3%制剂的杀成虫效果与氯菊酯15%制剂相似,但氯菊酯15%制剂对成虫羽化的抑制从未超过20%,而15%氯菊酯+3%吡丙醚处理对成虫羽化的抑制率为96%在ULV喷洒后保持这种高水平的抑制作用长达35天。幼虫指数(House和Breteau指数)表明,使用15%氯菊酯加3%吡丙醚制剂获得了更大的持久效果。
A new ultralow volume formulation (ULV) containing permethrin as an adulticidal active ingredient and the insect growth regulator (IGR) pyriproxyfen as a larvicide was developed and its efficacy evaluated in a field trial in Wanda, Misiones (Argentina). Two separate study areas were sprayed: one with a ULV formulation of permethrin 15% plus pyriproxyfen 3% and the other with permethrin 15% only. A third untreated area was kept as a control. Sentinel cages containing adult mosquitoes and jars containing Aedes aegypti larvae III/IV were placed in treated and control areas. The residual activity of the formulations was tested using 20 L water containers. The adulticide effect of permethrin 15% + pyriproxyfen 3% formulation was similar to the permethrin 15% formulation, however, the inhibition of adult emergence in the treatment with permethrin 15% never exceeded 20%, whereas the inhibition of adult emergence in the treatment with permethrin 15% plus pyriproxyfen 3% showed initial values of 96% maintaining this high level of inhibition up to 35 days after ULV spraying. Larval indexes (House and Breteau indexes) showed that a greater, long-lasting effect was obtained with the permethrin 15% plus pyriproxyfen 3% formulation.